Efficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome - Test2 - elhamkhani - TriplyDB

Efficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome

Efficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome

http://www.wikidata.org/entity/Q24684839

about

Novel pharmacology: asimadoline, a kappa-opioid agonist, and visceral sensation New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists Abdominal bloating: pathophysiology and treatment Brain-gut axis: from basic understanding to treatment of IBS and related disorders Stress and visceral pain: from animal models to clinical therapies Development, plasticity and modulation of visceral afferents.Review article: new receptor targets for medical therapy in irritable bowel syndrome Irritable bowel syndrome: current and emerging treatment options.Metabolic and toxicological considerations for the latest drugs used to treat irritable bowel syndrome.Treatment of irritable bowel syndrome: beyond fiber and antispasmodic agents.Scintigraphic biomarkers for colonic dysmotility.Evidence-based clinical practice guidelines for irritable bowel syndrome.Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: a review.Effects of peripherally restricted κ opioid receptor agonists on pain-related stimulation and depression of behavior in rats Drug management of visceral pain: concepts from basic research.Effects of peripheral κ opioid receptor activation on inflammatory mechanical hyperalgesia in male and female rats Psychopharmacological treatment and psychological interventions in irritable bowel syndrome.Visceral analgesics: drugs with a great potential in functional disorders?Medical management of irritable bowel syndrome in 2008: current and future directions.Updates on treatment of irritable bowel syndrome.Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles.Pain and inflammatory bowel disease.Current and novel therapeutic options for irritable bowel syndrome management.Asimadoline in the treatment of irritable bowel syndrome.Investigational agents for the irritable bowel syndrome.Existing and emerging therapies for irritable bowel syndrome.Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome.New treatments for IBS.The safety of novel drugs used to treat irritable bowel syndrome.Treatment of abdominal pain in irritable bowel syndrome.Emerging drug for diarrhea predominant irritable bowel syndrome.Neuroimmune factors in functional gastrointestinal disorders: A focus on irritable bowel syndrome.Human native kappa opioid receptor functions not predicted by recombinant receptors: Implications for drug design Asimadoline, a kappa-opioid agonist, and satiation in functional dyspepsia.

P2860

Q24644669-CD5CCDF7-D954-4DE1-A7FF-0B07C34287D7 Q26748617-983E08A8-D8D1-43A1-B05F-D6A06EC51FA6 Q26851622-1BDBED9A-69E8-4B8C-AEC2-5171BBC0A630 Q27024801-7F65038F-72E1-4392-B4A6-2B71481D7274 Q30459512-106C6D91-73C6-430A-8C99-D4E78887C4A4 Q33739750-ADF76B23-3773-455D-8D95-17C6534926BD Q33959307-C36AE9DF-D76C-4FF2-B21E-13AC0A713B70 Q34010550-20DFD34D-D2CA-4FAC-894F-D2F36BA475B6 Q34323319-62178826-D376-46B9-8035-817EA624B22F Q35018460-D2DDDB7F-A0EE-453F-96E2-7A9AAA34C870 Q35384517-87BB7472-5104-4785-AA51-E5D5127260C1 Q35513973-7BD8676C-CC14-41E4-BE47-69FEF16B1D71 Q35752958-491B67A5-61A4-480D-9F97-FE2BC3AADEED Q35776817-2AEAB335-D498-4300-A9D0-38B956389B40 Q35947915-18398627-E1C0-4A38-8B6F-F25B473F0DEB Q36188108-C7AC708D-A7E3-46B8-9BA3-9D160A7A13C8 Q36203967-2CF303AB-17C7-4A73-9ECC-8C4504C085C5 Q37118821-495B0000-02A6-4B53-AA9B-8A957215451F Q37141316-CC8BFD5B-58B0-4F4C-A6CC-A66302FD425C Q37156627-9751D91A-5D51-4CF7-BD49-BBCC2BC55026 Q37164063-2AC9A0EF-E09D-434D-AAE8-3DFB1451A501 Q37364689-43E5338E-903B-44F4-8572-B5B28043E248 Q37438547-B1A31BE8-E8EF-4020-9305-4ADF85D8B040 Q37784531-3DF246C8-D9BE-4DCA-9F4B-37B3062EAE34 Q37788218-F380004D-032F-4F09-BD33-7CA94DC4DE3A Q37857849-14CD9F64-BC8C-48E1-93E2-5DD90121F0DE Q37954521-816D8C33-66B0-40C1-8B41-9F2F7E98BDFA Q38059436-8D14F349-2679-4846-9EB3-D650975A353E Q38199522-B0B42501-F7EF-49E1-A4BA-76BDEFB73FAD Q38213185-401ADBB0-24DC-4A0A-816E-2AA8417A2D04 Q38366814-88D74A4E-2376-4058-8DA0-8BE27A15E697 Q39058964-FE87E427-4052-4A32-95CF-622AFA0D619A Q39522869-0F92A1EE-9BD8-435C-B1D3-82D9078957D3 Q41979327-00D91387-2E19-4E39-883A-F1B57DE1D38D

P2860

Efficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome

http://www.wikidata.org/entity/Q24684839

description

2007 nî lūn-bûn

@nan

2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Efficacy of on-demand asimadol ...... with irritable bowel syndrome

@ast

Efficacy of on-demand asimadol ...... with irritable bowel syndrome

@en

Efficacy of on-demand asimadol ...... with irritable bowel syndrome

@nl

type

label

Efficacy of on-demand asimadol ...... with irritable bowel syndrome

@ast

Efficacy of on-demand asimadol ...... with irritable bowel syndrome

@en

Efficacy of on-demand asimadol ...... with irritable bowel syndrome

@nl

prefLabel

Efficacy of on-demand asimadol ...... with irritable bowel syndrome

@ast

Efficacy of on-demand asimadol ...... with irritable bowel syndrome

@en

Efficacy of on-demand asimadol ...... with irritable bowel syndrome

@nl

P1433

Q24684839-93F155F3-FAB9-4AF7-A4F6-E48DEE508C7E

P1476

Q24684839-92382BDE-6BA7-44DA-89ED-123A72E0F46B

P2093

Q24684839-361B0AE1-E530-4070-9190-EBF7B7F059D4

Q24684839-5602642B-F8AC-447E-BB6A-823C6C5DF944

Q24684839-A22A744D-A558-4419-A6B5-DAC1B262B83F

Q24684839-BB5422E9-7693-4B94-ADB5-6B6EE81EA9EF

Q24684839-DD979CDF-2F0E-43BE-BC38-763207BDF939

Q24684839-ECD2AD9E-33E1-42AE-A36C-B5F191792701

P2860

Q24684839-290886F6-41FC-4EF3-9D99-3C8E5C63917F

Q24684839-2A957E4F-1406-42EB-9332-9B2A69DD4FF8

Q24684839-2BBE373A-7086-4C72-B2F8-626146A376DB

Q24684839-38084615-111D-451B-BFAA-8577466F341D

Q24684839-457BD178-D586-42A8-901A-E8B9E23B7560

Q24684839-4D306408-38F5-44C3-8494-E37FD7B9D0AC

Q24684839-5C148414-5DCA-44C0-9663-6B40C55B28AA

Q24684839-6374A2BD-7033-4F68-B785-4ECCD2A750BB

Q24684839-67F1897D-D5B7-4E5B-992D-CC327FB0F6FF

Q24684839-6AD033E0-E6D6-4A6E-922C-29381AC39028

P304

Q24684839-222BB2F7-1DAF-444B-AE8F-961AEC6EBF6B

P31

Q24684839-F9B36D36-092B-44DC-8C7C-C9DED99B6939

P3181

Q24684839-20AB80F8-F4A4-4E6E-80D5-DC53D59E15CF

P356

Q24684839-3D645B4C-611E-48B2-8D25-5A48D643EEB4

P407

Q24684839-E40D3556-4BB6-4651-9990-DCF3969BF600

P433

Q24684839-DCAD3EBF-5A34-45C0-9F06-1B217F78D50F

P478

Q24684839-E086D060-BA2B-4EE1-BE43-AF68C857A77F

P50

Q24684839-21B9BD68-B9F3-469F-8DBD-3743F3359CA1

Q24684839-6F19BE2D-3F52-4A6C-A98A-52B00C5DF833

Q24684839-D7D08FFA-C9ED-4DEA-BA17-0EF071703C83

P577

Q24684839-C98E1B46-2BD0-4E7A-B2F3-90B54FE53030

P5875

Q24684839-E1EE5B58-BE42-4750-B723-8A6C8A1DB8F4

P698

Q24684839-A1804365-0D8D-417B-8502-5BCFF4372229

P921

Q24684839-a36dfc51-0235-4170-b8b9-b4039b043e84

P932

Q24684839-7A0C5570-4F26-4D1A-85FD-63F675185677

P3181

P356

J.CGH.2007.07.011

P1433

Clinical Gastroenterology and Hepatology

P1476

Efficacy of on-demand asimadol ...... with irritable bowel syndrome

@en

P2093

Duane Burton

http://www.w3.org/2001/XMLSchema#string

Jean C Fox

http://www.w3.org/2001/XMLSchema#string

Julie Simonson

http://www.w3.org/2001/XMLSchema#string

Nancy Sullivan

http://www.w3.org/2001/XMLSchema#string

Sanna McKinzie

http://www.w3.org/2001/XMLSchema#string

Timothy Stanislav

http://www.w3.org/2001/XMLSchema#string

P2860

kappa-Opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system

The hospital anxiety and depression scale

The burden of illness of irritable bowel syndrome: current challenges and hope for the future

Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans.

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.

Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome.

How bad are the symptoms and bowel dysfunction of patients with the irritable bowel syndrome? A prospective, controlled study with emphasis on stool form

Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact.

Irritable bowel syndrome neuropharmacology. A review of approved and investigational compounds.

Irritable bowel syndrome: recent and novel therapeutic approaches.

P304

1268-75

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4114629

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.CGH.2007.07.011

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Alan R. Zinsmeister

Lawrence A. Szarka

Michael Camilleri

P577

2007-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5943760

http://www.w3.org/2001/XMLSchema#string

P698

17900994

http://www.w3.org/2001/XMLSchema#string

P921

P932

2128734

http://www.w3.org/2001/XMLSchema#string